These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 19001107)
21. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity. Finch NA; Zasowski EJ; Murray KP; Mynatt RP; Zhao JJ; Yost R; Pogue JM; Rybak MJ Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923869 [TBL] [Abstract][Full Text] [Related]
22. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Swanson DJ; Sung RJ; Fine MJ; Orloff JJ; Chu SY; Yu VL Am J Med; 1992 Jan; 92(1):61-8. PubMed ID: 1731511 [TBL] [Abstract][Full Text] [Related]
23. Protective effect of N-acetylcysteine from drug-induced ototoxicity in uraemic patients with CAPD peritonitis. Tokgoz B; Ucar C; Kocyigit I; Somdas M; Unal A; Vural A; Sipahioglu M; Oymak O; Utas C Nephrol Dial Transplant; 2011 Dec; 26(12):4073-8. PubMed ID: 21551083 [TBL] [Abstract][Full Text] [Related]
24. Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis*. Hanrahan TP; Harlow G; Hutchinson J; Dulhunty JM; Lipman J; Whitehouse T; Roberts JA Crit Care Med; 2014 Dec; 42(12):2527-36. PubMed ID: 25083977 [TBL] [Abstract][Full Text] [Related]
25. Assessment of initial serum vancomycin trough concentrations and their association with initial empirical weight-based vancomycin dosing and development of nephrotoxicity in children: a multicenter retrospective study. Matson KL; Shaffer CL; Beck GL; Simonsen KA Pharmacotherapy; 2015 Mar; 35(3):337-43. PubMed ID: 25756622 [TBL] [Abstract][Full Text] [Related]
26. Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center. Meng L; Wong T; Huang S; Mui E; Nguyen V; Espinosa G; Desai J; Holubar M; Deresinski S Pharmacotherapy; 2019 Apr; 39(4):433-442. PubMed ID: 30739349 [TBL] [Abstract][Full Text] [Related]
27. Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study. Bhatt-Mehta V; Schumacher RE; Faix RG; Leady M; Brenner T Pediatrics; 1999 Apr; 103(4):e48. PubMed ID: 10103340 [TBL] [Abstract][Full Text] [Related]
28. Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. Cohen E; Dadashev A; Drucker M; Samra Z; Rubinstein E; Garty M J Antimicrob Chemother; 2002 Jan; 49(1):155-60. PubMed ID: 11751780 [TBL] [Abstract][Full Text] [Related]
29. Vancomycin administration in continuous ambulatory peritoneal dialysis: the risk of ototoxicity. Gendeh BS; Gibb AG; Aziz NS; Kong N; Zahir ZM Otolaryngol Head Neck Surg; 1998 Apr; 118(4):551-8. PubMed ID: 9560111 [TBL] [Abstract][Full Text] [Related]
31. Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin. Masuda N; Maiguma T; Komoto A; Haruki Y; Sugiyama T; Kondo S; Teshima D Int J Clin Pharmacol Ther; 2015 Apr; 53(4):284-91. PubMed ID: 25740266 [TBL] [Abstract][Full Text] [Related]
32. Vancomycin-induced acute kidney injury detected by a prospective pharmacovigilance program from laboratory signals. Ramírez E; Jiménez C; Borobia AM; Tong HY; Medrano N; Krauel-Bidwell L; Carcas AJ; Selgas R; Frías J Ther Drug Monit; 2013 Jun; 35(3):360-6. PubMed ID: 23666575 [TBL] [Abstract][Full Text] [Related]
33. Relationship between vancomycin-associated nephrotoxicity and the number of combined nephrotoxic agents. Ueki T; Sanematsu E; Furuya Y; Shinohara Y; Murakami Y; Miyazaki A; Sakamoto Y; Nakashima MN; Nakashima M Pharmazie; 2020 Jun; 75(6):279-283. PubMed ID: 32539926 [TBL] [Abstract][Full Text] [Related]
34. Cisplatin ototoxicity: the importance of baseline audiometry. Nagy JL; Adelstein DJ; Newman CW; Rybicki LA; Rice TW; Lavertu P Am J Clin Oncol; 1999 Jun; 22(3):305-8. PubMed ID: 10362343 [TBL] [Abstract][Full Text] [Related]
35. Determinants of vancomycin nephrotoxicity when administered to outpatients as a continuous 24-hour infusion. Chambers ST; Long M; Gardiner SJ; Chin PKL; Yi M; Dalton SC; Drennan PG; Metcalf SCL Int J Antimicrob Agents; 2020 Jun; 55(6):105972. PubMed ID: 32298746 [TBL] [Abstract][Full Text] [Related]
36. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of area under the concentration-time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury. Muklewicz JD; Steuber TD; Edwards JD Int J Antimicrob Agents; 2021 Jan; 57(1):106234. PubMed ID: 33232734 [TBL] [Abstract][Full Text] [Related]
39. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Jeffres MN; Isakow W; Doherty JA; Micek ST; Kollef MH Clin Ther; 2007 Jun; 29(6):1107-15. PubMed ID: 17692725 [TBL] [Abstract][Full Text] [Related]
40. Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion. Mousavi M; Zapolskaya T; Scipione MR; Louie E; Papadopoulos J; Dubrovskaya Y Pharmacotherapy; 2017 Mar; 37(3):379-385. PubMed ID: 28079263 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]